《Application value of ATP based bioluminescence tumor chemosensitivity assay in the chemotherapy for hydrothorax caused by nonsmall cell lung cancer》.pdfVIP

Chinese-German J Clin Oncol May 2013, Vol. 12, No. 5, P210–P212 DOI 10.1007/s10330-013-1153-7 Application value of ATP based bioluminescence tumor chemosensitivity assay in the chemotherapy for hydrothorax caused by non-small cell lung cancer Kaijian Le, Yuming Jia, Jing Wang, Maoqiong Jiang Department of Oncology, The No. 2 People’s Hospital of Yibin, Yibin 644000, China Received: 15 February 2013 / Revised: 4 March 2013 / Accepted: 5 April 2013 © Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg 2013 Abstract Objective: The aim of the study was to investigate the clinical value and application of ATP based biolumines- cence tumor chemosensitivity assay (ATP-TCA) in the chemotherapy for hydrothorax caused by non-small cell lung cancer (NSCLC). Methods: Hydrothorax specimens from 120 NSCLC patients were analyzed by ATP-TCA and the most sensitive chemotherapeutic drugs were used in NSCLC patients (treatment group). At the same time, 56 NSCLC patients with hydro- thorax were admitted in our Hospital (Department of Oncology, The No. 2 People’s Hospital of Yibin, China) and given che- motherapy without guidance of the ATP-TCA (control group). Before the third chemotherapeutic cycle, clinical outcomes were analyzed in the two groups. Results: Effective rate of hydrothorax in treatment group was 67%, while 46% in control group (P 0.05). In refractory hydrothorax patients, they were 69% and 40% (P 0.05), respectively. In vitro results correlated well with clinical outcomes (P 0.01). Conclusion: Effective rate of chemotherapy for hydrothorax in NSCLC is higher in treatment group than that in control group. ATP-TCA is especially helpful for